WBR0509
| Author | [[PageAuthor::Serge Korjian M.D. (Reviewed by Serge Korjian]] |
|---|---|
| Exam Type | ExamType:: |
| Main Category | |
| Sub Category | |
| Prompt | Prompt:: |
| Answer A | AnswerA:: |
| Answer A Explanation | AnswerAExp:: |
| Answer B | AnswerB:: |
| Answer B Explanation | AnswerBExp:: |
| Answer C | AnswerC:: |
| Answer C Explanation | AnswerCExp:: |
| Answer D | AnswerD:: |
| Answer D Explanation | AnswerDExp:: |
| Answer E | AnswerE:: |
| Answer E Explanation | AnswerEExp:: |
| Right Answer | RightAnswer:: |
| Explanation | [[Explanation:: Educational Objective: |
| Approved | Approved:: |
| Keyword | |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |
|ExamType=USMLE Step 1 |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |MainCategory=Pharmacology |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |SubCategory=Reproductive |MainCategory=Pharmacology |MainCategory=Pharmacology |SubCategory=Reproductive |Prompt=A 31-year-old man presents to the dermatology clinic for hair loss. The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex. He also explains that he has a strong family history of androgenetic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful. You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug? |AnswerA=Phosphodiesterase 5 (PDE5) inhibitor |AnswerAExp=Sildenafil and tadalafil are examples of phosphodiesterase 5 (PDE5) inhibitors. These drugs are used to treat erectile dysfunction and are not used for the treatment of androgenetic alopecia. |AnswerB=Competitive inhibitor of testosterone binding at androgen receptors |AnswerBExp=Flutamide is a nonsteroidal antiandrogen that acts as a competitive inhibitor of testosterone binding at androgen receptors. It is used in the treatment of prostate cancer and is not used for the treatment of androgenetic alopecia. |AnswerC=Aromatase inhibitor |AnswerCExp=Exemestane acts as an aromatase inhibitor to decrease peripheral estrogen production. It is used in the treatment of estrogen receptor-positive breast cancer and cannot be used to treat androgenetic alopecia. |AnswerD=Agonist of luteinizing hormone-releasing hormone (LHRH) |AnswerDExp=Leuprolide acts as an agonist of luteinizing hormone-releasing hormone (LHRH) causing a disruption of gonadotropin release if given continuously. It is used in the treatment of prostate cancer, endometriosis, and leiomyoma and cannot be used to treat androgenetic alopecia. |AnswerE=Selective inhibitor of 5-alpha-reductase |AnswerEExp=Finasteride is a selective inhibitor of 5-alpha-reductase used in the treatment of androgenetic alopecia. |RightAnswer=E |WBRKeyword=Androgenetic alopecia, Male pattern baldness, baldness, Finasteride, 5-alpha-reductase, DHT, |Approved=No }}